Abstract: A phytochemical composition for treatment of sickle cell anemia has been developed. The composition is a solid mixture of inorganic salts and various organic compounds of herbal origin and obtained by extracting a mixture of five herbs namely Piper guineenses seeds, Pterocarpus osum stem, Eugenia carophyllum fruit, Sorghum bicolor leaves and Curcuma longa tuber with aquous solution of sodium/potassium bicarbonate and sodium/potassium carbonate and then concentrating the extract to obtain a powder. Also described are methods of preparation of extraction product and method of its use for treatment of sickle cell disease afflicted patients.

Abstract: This invention relates to a process for preparation of taxanes comprising subjecting 7,10-diprotected intermediates 7-O-(2-haloacyl)baccatin III 6c or 7,10-O-di-(2-haloacyl)-10-deacetylbaccatin III 6b to a step of coupling with (4S,5R)-3-[(2-alkyl/aryl-2-trialkylsilyl)ethoxy-carbonyl]-4-aryl-2-substituted-1,3-oxazolidine-5-carboxylic acid 1 in the presence of a condensation agent, an activating agent and an aromatic hydrocarbon to obtain 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3(2-unsubstituted/substituted-2-trialkylsilyl)-ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O [2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-unsubstituted/substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]-10-deacetylbaccatin III 7b; treating the coupled products 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O-[2[(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-s

Abstract: This invention relates to a process for preparation of taxanes comprising subjecting 7,10-diprotected intermediates 7-O-(2-haloacyl)baccatin III 6c or 7,10-O-di-(2-haloacyl)-10-deacetylbaccatin III 6b to a step of coupling with (4S,5R)-3-[(2-alkyl/aryl-2-trialkylsilyl)ethoxy-carbonyl]-4-aryl-2-substituted-1,3-oxazolidine-5-carboxylic acid 1 in the presence of a condensation agent, an activating agent and an aromatic hydrocarbon to obtain 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3(2-unsubstituted/substituted-2-trialkylsilyl)-ethoxycarbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-unsubstituted/substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]-10-deacetylbaccatin III 7b; treating the coupled products 7-O-[2-(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-substituted-2-trialkylsilyl)ethoxy-carbonyl-1,3-oxazolidinyl-5-carbonyl]baccatin III 7a or 7,10-di-O-[2[(haloacyl)]-13-[(4S,5R)-4-aryl-2-substituted-3-(2-su

Abstract: A process for the preparation of taxanes comprising wherein R is a tert. butoxycarbonyl or benzoyl group; PMP is p-methoxyphenyl group; G1 is acetyl group; G2 is haloacetyl group comprising a) protecting the C-7 hydroxyl group of 10-deacetylbaccatin III with haloacetyl chlorides and then acetylating the C-10 hydroxyl group with acetyl chloride to obtain a protected 10-deacetylbaccatin III (1); b) subjecting the protected 10-deacetylbaccatin III (1) to coupling with an oxazolidine-5-caboxylic acid of formula 2 wherein R is tert. butoxycarbonyl or benzoyl; PMP is p-methoxyphenyl group in the presence of a condensation agent and an activating agent to obtain C-13 esters of formula 3; c) treating the coupled products 3 with weak acidic medium to open the oxazolidine ring to obtain intermediates of formula 4; wherein R is a tert.

Abstract: A process for the preparation of taxanes including paclitaxel, docetaxel, and structurally similar analogs, as well as intermediates produced by the process.

Abstract: A process for the purification of paclitaxel or docetaxel comprising: (a) mixing crude paclitaxel with a mixture of solvents such as alkane and chlorinated alkane, filtering the solid followed by drying to obtain paclitaxel or docetaxel of increased purity; (b) repeating step (a) one or more times to obtain paclitaxel or docetaxel of increased purity; (c) dissolving the solid obtained from step (b) in alkyl ketone followed by adding alkane thereto, filtering and drying the solid thus formed to obtain paclitaxel or docetaxel of increased purity; (d) repeating step (c) one or more times to increase the purity of paclitaxel or docetaxel; (e) dissolving the paclitaxel or docetaxel obtained from step (d) in alkanol and then adding water, filtering and drying the solid thus formed, to obtain paclitaxel of increased purity; (f) dissolving the solid obtained from step (e) in alkyl ketone, filtering, followed by adding alkane to the filtrate, filtering and drying the solid thus formed to obtain pure paclitaxel or pure

Abstract: A process for converting paclitaxel or docetaxel to the respective trihydrate characterized by very high purity, comprises dissolving either paclitaxel or docetaxel in a mixture of alkane and chlorinated alkane to provide a crude product of 65-75% assay and dissolving the crude product in an alkyl ketone, followed by addition of an alkane to provide a product of increased chromatographic purity; dissolving the product of increased chromatographic purity in an aliphatic nitrile, with addition of water to precipitate taxane trihydrate.

Abstract: A process for the preparation of paclitaxel trihydrate and doctaxel trihydrate comprising (a) treating taxane selected from paclitaxel and docetaxel with a mixture of alkane and chlorinated alkane to obtain a crude product of 65-75% assay, (b) dissolving the crude product thus obtained in alkyl ketone followed by slow addition of an alkane to increase chromatographic purity, (c) dissolving the taxane of step (b) in an aliphatic nitrile at a temperature of 50-70° C., (d) adding purified water to the product of step (c) to precipitate taxane trihydrate; and (e) filtering and drying the product of step (d) to obtain taxane trihydrate of C.P. >99.5% and 98-102% assay.

Abstract: A process for the preparation of taxanes comprising 1

Abstract: This invention relates to a process for preparation of taxanes comprising

Abstract: A process for the purification of paclitaxel comprising: (a) mixing crude paclitaxel with a mixture of solvents such as alkane and chlorinated alkane, filtering the solid followed by drying to obtain paclitaxel of increased purity; (b) repeating step (a) one or more times to obtain paclitaxel of increased purity; (c) dissolving the solid obtained from step (b) in alkyl ketone followed by adding alkane thereto, filtering and drying the solid thus formed to obtain paclitaxel of increased purity; (d) repeating step (c) one or more times to increase the purity of paclitaxel; (e) dissolving the paclitaxel obtained from step (d) in alkanol and then adding water, filtering and drying the solid thus formed, to obtain paclitaxel of increased purity; and (f) dissolving the solid obtained from step (e) in alkyl ketone, filtering, followed by adding alkane to the filtrate, filtering and drying the solid thus formed to obtain pure paclitaxel.

Abstract: A process for the preparation of taxanes including paclitaxel, docetaxel, and structurally similar analogs, as well as intermediates produced by the process.

Abstract: 3-(alk-2-ynyloxy)carbonyl-5-oxazolidine carboxylic acid and its analogs having a formula 1